ResMed Inc. (LON:0KW4)

ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of GBP 27.88 billion. The enterprise value is 27.47 billion.

Market Cap	27.88B
Enterprise Value	27.47B

Important Dates

The last earnings date was Thursday, October 23, 2025.

Earnings Date	Oct 23, 2025
Ex-Dividend Date	Aug 14, 2025

Share Statistics

Current Share Class	145.97M
Shares Outstanding	n/a
Shares Change (YoY)	-0.28%
Shares Change (QoQ)	-0.09%
Owned by Insiders (%)	0.53%
Owned by Institutions (%)	74.24%
Float	145.03M

Valuation Ratios

The trailing PE ratio is 26.06 and the forward PE ratio is 22.52.

PE Ratio	26.06
Forward PE	22.52
PS Ratio	7.13
PB Ratio	6.12
P/TBV Ratio	14.25
P/FCF Ratio	21.19
P/OCF Ratio	19.90
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.26, with an EV/FCF ratio of 20.88.

EV / Earnings	25.68
EV / Sales	6.88
EV / EBITDA	18.26
EV / EBIT	20.48
EV / FCF	20.88

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.14.

Current Ratio	2.89
Quick Ratio	1.87
Debt / Equity	0.14
Debt / EBITDA	0.43
Debt / FCF	0.48
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.41% and return on invested capital (ROIC) is 16.93%.

Return on Equity (ROE)	25.41%
Return on Assets (ROA)	14.18%
Return on Invested Capital (ROIC)	16.93%
Return on Capital Employed (ROCE)	24.99%
Revenue Per Employee	368,980
Profits Per Employee	100,916
Employee Count	10,600
Asset Turnover	0.68
Inventory Turnover	2.03

Taxes

In the past 12 months, ResMed has paid 225.38 million in taxes.

Income Tax	225.38M
Effective Tax Rate	17.40%

Stock Price Statistics

The stock price has increased by +2.33% in the last 52 weeks. The beta is 0.83, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	+2.33%
50-Day Moving Average	268.38
200-Day Moving Average	252.03
Relative Strength Index (RSI)	34.52
Average Volume (20 Days)	420

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.60

Income Statement

In the last 12 months, ResMed had revenue of GBP 3.91 billion and earned 1.07 billion in profits. Earnings per share was 7.27.

Revenue	3.91B
Gross Profit	2.37B
Operating Income	1.31B
Pretax Income	1.30B
Net Income	1.07B
EBITDA	1.44B
EBIT	1.31B
Earnings Per Share (EPS)	7.27

Balance Sheet

The company has 1.03 billion in cash and 629.64 million in debt, giving a net cash position of 399.86 million.

Cash & Cash Equivalents	1.03B
Total Debt	629.64M
Net Cash	399.86M
Net Cash Per Share	n/a
Equity (Book Value)	4.55B
Book Value Per Share	31.20
Working Capital	1.76B

Cash Flow

In the last 12 months, operating cash flow was 1.40 billion and capital expenditures -85.55 million, giving a free cash flow of 1.32 billion.

Operating Cash Flow	1.40B
Capital Expenditures	-85.55M
Free Cash Flow	1.32B
FCF Per Share	n/a

Margins

Gross margin is 60.69%, with operating and profit margins of 33.52% and 27.35%.

Gross Margin	60.69%
Operating Margin	33.52%
Pretax Margin	33.11%
Profit Margin	27.35%
EBITDA Margin	36.87%
EBIT Margin	33.52%
FCF Margin	33.64%

Dividends & Yields

This stock pays an annual dividend of 1.67, which amounts to a dividend yield of 0.67%.

Dividend Per Share	1.67
Dividend Yield	0.67%
Dividend Growth (YoY)	6.74%
Years of Dividend Growth	3
Payout Ratio	22.31%
Buyback Yield	0.28%
Shareholder Yield	0.95%
Earnings Yield	3.84%
FCF Yield	4.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.67 and a Piotroski F-Score of 6.

Altman Z-Score	12.67
Piotroski F-Score	6